MaaT Pharma and Skyepharma have successfully completed the construction of Europe's largest manufacturing facility dedicated to microbiome ecosystem therapies.
This state-of-the-art facility spans an impressive 17,200 square feet and is specifically designed to support both clinical and commercial-scale manufacturing of microbiome ecosystem therapies.
The new facility not only enhances bioproduction capabilities but also makes a valuable contribution to the biotech ecosystem in France and Europe as a whole.
The first production campaign is scheduled to commence in the new plant by the end of the third quarter of 2023. In addition, the facility will lead to the creation of around a dozen jobs, which is a positive development for the biopharmaceutical sector.
This signifies the start of a new era in the manufacturing of microbiome ecosystem therapies in Europe, with the potential to provide innovative treatment options for a wide range of medical conditions.
Name MaaT Pharma and Skyepharma
Type New Construction